Study guide
12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
Key Takeaways Explain This Topic AI
Cholinesterase inhibitors can cause bradycardia and syncope, so use them cautiously in conduction disease, and avoid anticholinergics that cancel their effect.
In Parkinson disease, avoid metoclopramide, prochlorperazine, haloperidol and risperidone; domperidone (maximum 30 mg/day) is preferred for nausea and quetiapine or clozapine for psychosis.
Medication-overuse headache occurs with triptans, opioids or combination analgesics on 10 or more days a month, or simple analgesics on 15 or more days.
CBT-I is first-line for insomnia, and sedating antihistamines and benzodiazepines are avoided in older adults.
Restless legs syndrome is managed first by checking ferritin, removing aggravating drugs such as diphenhydramine, and non-drug measures.
Last updated: October 2026
Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
These neurological conditions are common in community practice. Each has a characteristic medication-safety trap: anticholinergic burden in dementia, dopamine blockers in Parkinson disease, medication overuse in migraine, sedative hypnotics in older adults, and drug-induced restless legs. PEBC sample items have tested several of these (cholinesterase inhibitor cautions, drugs that worsen Parkinson disease, and first steps for restless legs).
1. Dementia (Alzheimer Disease and Related Dementias)
Cholinesterase inhibitors (ChEIs):
Agents: donepezil, rivastigmine (oral or patch), galantamine , for mild to moderate Alzheimer disease. They also help dementia with Lewy bodies and Parkinson disease dementia (rivastigmine).
Benefit: modest; assess cognition and function after about 3 to 6 months.
Adverse effects: nausea, vomiting, diarrhea, weight loss, vivid dreams (dose donepezil in the morning if this occurs), and vagotonic effects : bradycardia, heart block and syncope . Use them cautiously in conduction disease (for example, left bundle branch block or sick sinus syndrome) and with other rate-slowing drugs such as beta-blockers.
Memantine (an NMDA antagonist) is used in moderate to severe disease, alone or with a ChEI. Reduce the dose in severe renal impairment. It can cause dizziness and confusion.
Avoid anticholinergics: oxybutynin, diphenhydramine, tricyclics and paroxetine worsen cognition and cancel out ChEI effects. Combining a ChEI with an anticholinergic bladder drug is a classic prescribing cascade.
Behavioural and psychological symptoms: treat non-drug causes first (pain, constipation, infection, environment). Antipsychotics are reserved for severe aggression or psychosis with risk of harm, at the lowest dose for the shortest time. In Canada, risperidone is indicated for short-term management of severe aggression in Alzheimer dementia. All antipsychotics carry a boxed warning for increased mortality and stroke in dementia (section 13.3).
2. Parkinson Disease
Drug class Examples Key points
Levodopa/carbidopa Immediate- and controlled-release Most effective symptomatic therapy. Dietary protein competes for absorption. Long-term use brings wearing-off and dyskinesias
Dopamine agonists Pramipexole, ropinirole, rotigotine patch Used in younger patients. Impulse-control disorders (gambling, shopping, hypersexuality), sudden sleep attacks , hallucinations and edema
MAO-B inhibitors Rasagiline, selegiline Mild benefit. Serotonergic and sympathomimetic interactions (meperidine, dextromethorphan, some antidepressants)
- COMT inhibitor Entacapone Extends each levodopa dose; colours the urine orange
- Amantadine Reduces levodopa-induced dyskinesia. Livedo reticularis; renal dose adjustment
Caution
Avoid central dopamine (D2) blockers in Parkinson disease:
Never use: metoclopramide, prochlorperazine, haloperidol, and most other antipsychotics, including risperidone. They worsen motor symptoms and can trigger severe rigidity.
Nausea: domperidone does not cross the blood-brain barrier and is preferred for nausea (watch the QT interval: maximum 30 mg/day in Canada).
Psychosis: quetiapine or clozapine are preferred.
Never stop levodopa abruptly. Withdrawal can cause a syndrome resembling neuroleptic malignant syndrome.
3. Migraine
Acute treatment:
First line: NSAIDs (ibuprofen, naproxen, ASA) or acetaminophen, taken early in the attack.
Triptans (sumatriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan) for moderate to severe attacks. They are contraindicated in coronary or cerebrovascular disease and uncontrolled hypertension , and serotonin syndrome is a theoretical concern with SSRIs. A second dose may be taken after 2 hours if the headache returns.
Antiemetics: metoclopramide or domperidone help nausea and absorption.
Avoid opioids and butalbital combinations.
Medication-overuse headache: risk rises when triptans, opioids or combination analgesics are used on 10 or more days a month , or simple analgesics on 15 or more days a month . Patients reaching these thresholds need preventive therapy and withdrawal of the overused drug.
Prevention: consider it when attacks are frequent (for example, 4 or more headache days a month) or disabling.
Beta-blockers: propranolol, metoprolol.
Amitriptyline.
Topiramate: teratogenic; reduces hormonal contraceptive efficacy at higher doses; cognitive slowing and paresthesias.
Candesartan.
CGRP monoclonal antibodies: erenumab, galcanezumab, fremanezumab, eptinezumab.
OnabotulinumtoxinA for chronic migraine.
Allow 2 to 3 months at an adequate dose before judging a preventive.
Pregnancy: acetaminophen is preferred, and sumatriptan has the most pregnancy data. Valproate is avoided in anyone who could become pregnant.
4. Insomnia
First-line: cognitive behavioural therapy for insomnia (CBT-I). It includes sleep restriction, stimulus control and cognitive techniques, and is more durable than drugs.
When drugs are used: use the lowest dose for the shortest time, and screen for causes (pain, depression, sleep apnea, caffeine, diuretics, stimulants).
Zopiclone: 3.75 mg in older adults (maximum 7.5 mg). Bitter taste and next-morning impairment.
Zolpidem sublingual: lower doses for women.
Low-dose doxepin (3 to 6 mg) for sleep maintenance.
Lemborexant , an orexin receptor antagonist.
Benzodiazepines are generally avoided in older adults: falls, fractures, cognitive impairment and motor vehicle crashes (Beers Criteria).
Avoid sedating antihistamines (diphenhydramine, doxylamine) in older adults because of anticholinergic effects and tolerance within days.
Melatonin is a natural health product. It is most useful for circadian rhythm problems such as jet lag and delayed sleep phase.
5. Restless Legs Syndrome (RLS)
RLS is an urge to move the legs, usually with uncomfortable sensations. It starts or worsens at rest and in the evening, and is relieved by movement.
Look for causes and aggravating drugs:
Check ferritin and iron studies. Supplement iron if ferritin is below about 75 µg/L.
Aggravating drugs: sedating antihistamines (diphenhydramine), antidepressants (SSRIs, SNRIs, mirtazapine), antipsychotics, metoclopramide, and alcohol or caffeine.
Non-drug first steps:
- moderate exercise, stretching, massage and a warm bath before bed;
- regular sleep habits;
reducing caffeine and alcohol.
Drug therapy for persistent symptoms: current guidelines favour alpha-2-delta ligands (gabapentin, pregabalin) first. Dopamine agonists (pramipexole, ropinirole) are now used more cautiously because of augmentation : symptoms that start earlier in the day, become more intense, and spread to the arms.